Pages that link to "Q51037995"
Jump to navigation
Jump to search
The following pages link to Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative (Q51037995):
Displaying 35 items.
- In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease (Q28830911) (← links)
- The oligomeric states of the purified sigma-1 receptor are stabilized by ligands (Q33931257) (← links)
- The sigma-1 receptor chaperone as an inter-organelle signaling modulator (Q34356970) (← links)
- Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model (Q34461389) (← links)
- Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism (Q35154720) (← links)
- The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice (Q35538511) (← links)
- Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS) (Q35811244) (← links)
- The sigma-1 receptors are present in monomeric and oligomeric forms in living cells in the presence and absence of ligands (Q35846559) (← links)
- The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements (Q35856904) (← links)
- Nootropics with potential to (re)build neuroarchitecture. (Q36639568) (← links)
- Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. (Q38022265) (← links)
- Selective sigma-1 receptor antagonists for the treatment of pain. (Q38235503) (← links)
- Investigational sigma-1 receptor antagonists for the treatment of pain. (Q38513640) (← links)
- Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease. (Q38743344) (← links)
- New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition. (Q38842928) (← links)
- Role of σ1 Receptors in Learning and Memory and Alzheimer's Disease-Type Dementia (Q38896662) (← links)
- Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases (Q39169781) (← links)
- Emerging amyloid and tau targeting treatments for Alzheimer's disease (Q39296311) (← links)
- Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. (Q39296351) (← links)
- Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. (Q42020086) (← links)
- Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease (Q44363046) (← links)
- Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress. (Q46263489) (← links)
- In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome (Q47319838) (← links)
- Altered sigma-1 receptor expression in two animal models of cognitive impairment (Q48026390) (← links)
- Systolic blood pressure as a potential target of sigma-1 receptor agonist therapy (Q48242748) (← links)
- Sigma-1 Receptor in Motoneuron Disease (Q48258033) (← links)
- Neuroprotective effect of a new photobiomodulation technique against Aβ25-35 peptide-induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested. (Q55421100) (← links)
- Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease (Q64067761) (← links)
- Sigma-1 Receptor Activation Induces Autophagy and Increases Proteostasis Capacity In Vitro and In Vivo (Q64071931) (← links)
- Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways (Q64240263) (← links)
- Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years (Q89805585) (← links)
- Mutational Analysis of Sigma-1 Receptor's Role in Synaptic Stability (Q90679929) (← links)
- Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo (Q90691238) (← links)
- A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study (Q92136058) (← links)
- Efficacy of THN201, a Combination of Donepezil and Mefloquine, to Reverse Neurocognitive Deficits in Alzheimer's Disease (Q96953332) (← links)